Nomura released a research report stating that the target price for Kangfang Biotech is HK$138.29 and a “buy” rating. Nomura said that before the opening of the Hong Kong stock market on September 29, Kangfang Biotech and its overseas partner Summit Therapeutics announced that Summit had received a strategic investment of 2 billion US dollars from AstraZeneca. AstraZeneca's $2 billion investment in Summit's convertible preferred stock is equivalent to about 12% of Summit's common stock. The two sides will also cooperate to evaluate visonetutamab sonesitatug vedotin, a CLDN 18.2 ADC drug authorized by AstraZeneca from a joint venture between Konoia and Lepbiotech, along with evosimab. The bank believes that this is good news for the development of evosimab in the global market, and evosimab is an integral part of Kangfang Biotech's core values.

Zhitongcaijing · 3d ago
Nomura released a research report stating that the target price for Kangfang Biotech is HK$138.29 and a “buy” rating. Nomura said that before the opening of the Hong Kong stock market on September 29, Kangfang Biotech and its overseas partner Summit Therapeutics announced that Summit had received a strategic investment of 2 billion US dollars from AstraZeneca. AstraZeneca's $2 billion investment in Summit's convertible preferred stock is equivalent to about 12% of Summit's common stock. The two sides will also cooperate to evaluate visonetutamab sonesitatug vedotin, a CLDN 18.2 ADC drug authorized by AstraZeneca from a joint venture between Konoia and Lepbiotech, along with evosimab. The bank believes that this is good news for the development of evosimab in the global market, and evosimab is an integral part of Kangfang Biotech's core values.